文献速递核素与放射性配体治疗

转移性胃肠胰神经内分泌肿瘤患者接受肽受体放射性核素治疗期间的生活质量:临床常规监测项目数据

Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
PubMed 文献 · J Nucl Med · 2018-07-24

该研究基于临床常规EORTC QLQ-C30监测数据,评估61例转移性胃肠胰神经内分泌肿瘤患者从首次肽受体放射性核素治疗至首次再分期期间的健康相关生活质量,并与一般人群常模比较。结果显示整体生活质量稳定,但小肠NET患者腹泻改善16分、女性小肠NET患者食欲丧失改善17分,而较年长小肠NET患者躯体和社会功能下降;除腹泻和食欲丧失外,患者首次再分期时评分未达一般人群水平。

要点

  • 整体生活质量在PRRT期间保持稳定,但较一般人群存在多项损害。
  • 小肠NET患者腹泻从基线至首次再分期改善16分,属中等偏大变化。
  • 仅女性小肠NET患者食欲丧失出现17分的临床相关改善。

核心结论

  • 分析支持既往关于PRRT期间整体生活质量稳定的发现,但需考虑与一般人群相比的显著生活质量损害及潜在的特定亚组模式。

研究设计与样本

  • 数据来自临床常规生活质量监测,使用欧洲癌症研究与治疗组织核心生活质量问卷EORTC QLQ-C30。
  • 患者接受4-6周期177Lu-DOTATATE或90Y-DOTATOC治疗。
  • 纳入分析需至少一次PRRT前生活质量评估和至少一次治疗结束时或治疗完成后的生活质量评估。
  • 采用线性混合模型分析生活质量随时间的变化。
  • 共61例胃肠胰NET患者符合分析条件,其中小肠NET 37例、胰腺NET 24例。

主要发现

  • 小肠NET患者腹泻从基线至首次再分期明确改善,下降16分,代表中等偏大变化。
  • 仅女性小肠NET患者观察到食欲丧失临床相关下降17分。
  • 其他生活质量变化也限于社会人口学或临床亚组,且主要反映改善,但较年长小肠NET患者躯体功能和社会功能评分下降。
  • 与一般人群常模相比,患者存在腹泻、疲乏、食欲丧失、躯体功能、社会功能、角色功能及整体生活质量损害。
  • 除腹泻和食欲丧失外,患者首次再分期时评分未达一般人群水平。

关键数值与推荐

  • 小肠NET患者腹泻评分从基线至首次再分期下降16分。
  • 女性小肠NET患者食欲丧失评分下降17分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with metastatic gastroenteropancreatic neuroendocrine tumors (NETs), we evaluated health-related quality of life (HRQoL) from the first peptide receptor radionuclide therapy (PRRT) to the first restaging and compared the scores with general-population (GP) norms. Methods: The data were from routine HRQoL monitoring using the core quality-of-life questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30). Patients received 4-6 cycles of 177Lu-DOTATATE or 90Y-DOTATOC. To be eligible for analysis, patients had to have at least one HRQoL assessment before PRRT and at least one HRQoL assessment at the end of or after treatment completion. Linear mixed models were used to consider HRQoL changes over time. Results: In total, 61 gastroenteropancreatic NET patients (small-intestine NETs, n = 37; pancreatic NETs, n = 24) were eligible for analysis. Clear improvements from baseline to the first restaging were found for diarrhea in small-intestine NET patients, showing a decrease of 16 points, which represents a moderately large change. We observed a clinically relevant decrease in appetite loss (17 points), but for female small-intestine NET patients only. Other HRQoL changes were also restricted to sociodemographic or clinical subgroups and mainly reflected improvements, except for physical and social functioning, which showed decreasing scores in older small-intestine NET patients. Compared with HRQoL GP norms, patients had impairments consisting of diarrhea; fatigue; appetite loss; reduced physical, social, and role functioning; and reduced global HRQoL. Except for diarrhea and appetite loss, patient scores at the first restaging did not reach GP levels. Conclusion: Our analyses support previous findings of overall stable HRQoL under PRRT. Yet, significant HRQoL impairments compared with the GP and potentially specific subgroup patterns need to be considered.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Martini C, Buxbaum S, Rodrigues M, et al. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine. J Nucl Med. 2018. PMID: 30042164. doi:10.2967/jnumed.117.204834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。